Indeed, since the identification of NPM–ALK and other ALK fusions as oncogenes for ALCL and inflammatory myofibroblastic tumors,6, 16, 17 several pharmaceutical companies developed ALK-specific TKIs. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.